MR1 Antibody (YA4415)(PBS only)

Cat. No.: HY-P84718A: Data Sheet User Guide for Antibodies
FAQs
Technical Support

MR1 Antibody (YA4415) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MR1.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

MR1 Antibody (YA4415) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MR1.

Host

Mouse

Molecular Weight

Predicted band size: 39.4 kDa;

Observed band size: 37 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q95460

Gene ID

3140 [NCBI]

Immunogen

Purified recombinant fragment of human MR1 (AA: extra(23-302)) expressed in E. Coli.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:200-1:1000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:200-1:1000
FC FC: Flow Cytometry	1:200-1:400
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:10000

Purity	affinity purified.	Conjugation	Non-conjugated
Isotype	IgG2a

Appearance

Liquid

Formulation

Supplied in PBS, pH 7.4.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Antigen-presenting molecule specialized in displaying microbial pyrimidine-based metabolites to alpha-beta T cell receptors (TCR) on innate-type mucosal-associated invariant T (MAIT) cells (PubMed:19416870, PubMed:23457030, PubMed:22692454, PubMed:23051753, PubMed:24101382, PubMed:23846752, PubMed:26795251). In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1.2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers (PubMed:20581831, PubMed:24101382, PubMed:24695216, PubMed:26795251). Signature pyrimidine-based microbial antigens are generated via non-enzymatic condensation of metabolite intermediates of the riboflavin pathway with by-products arising from other metabolic pathways such as glycolysis. Typical potent antigenic metabolites are 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), products of condensation of 5-amino-6-D-ribityaminouracil (5-A-RU) with glyoxal or methylglyoxal by-products, respectively (PubMed:24695216, PubMed:32958637, PubMed:32709702). May present microbial antigens to various TRAV1-2-negative MAIT cell subsets, providing for unique recognition of diverse microbes, including pathogens that do not synthesize riboflavin (PubMed:27527800, PubMed:31113973). Upon antigen recognition, elicits rapid innate-type MAIT cell activation to eliminate pathogenic microbes by directly killing infected cells (PubMed:23846752, PubMed:24695216, PubMed:27527800). During T cell development, drives thymic selection and post-thymic terminal differentiation of MAIT cells in a process dependent on commensal microflora (By similarity). Acts as an immune sensor of cancer cell metabolome (PubMed:31959982). May present a tumor-specific or -associated metabolite essential for cancer cell survival to a 'pan-cancer' TCR consisting of TRAV38.2-DV8*TRAJ31 alpha chain paired with a TRBV25.1*TRBJ2.3 beta chain on a non-MAIT CD8-positive T cell clone (MC.7.G5), triggering T cell-mediated killing of a wide range of cancer cell types (PubMed:31959982); Allele MR1*01: Presents microbial-derived metabolite 5-OP-RU to semi-invariant TRAV1.2-TRAJ33-TRBV6.1 (A-F7) TCR on MAIT cells (PubMed:39589872). Presents nucleobase carbonyl adducts generated during oxidative stress. Captures M3Ade, a nucleobase adduct composed of one adenine modified by a malondialdehyde trimer, for recognition by MR1-restricted T cell clones expressing a polyclonal TCR repertoire (PubMed:39701104). Displays moderate binding affinity toward tumor-enriched pyridoxal and pyridoxal 5'-phosphate antigens (PubMed:39589872); Allele MR1*04: Presents tumor-enriched metabolite pyridoxal to pan-cancer 7.G5 TCR on T cells enabling preferential recognition of cancer cells. May act as an alloantigen

Subcellular Localization：Cell membrane; Single-pass type I membrane protein; Endoplasmic reticulum membrane; Single-pass type I membrane protein; Golgi apparatus membrane; Single-pass type I membrane protein; Early endosome membrane; Single-pass type I membrane protein; Late endosome membrane; Single-pass type I membrane protein; Cell membrane; Single-pass type I membrane protein; Endoplasmic reticulum membrane; Single-pass membrane protein; Cell membrane; Single-pass type I membrane protein; Endoplasmic reticulum membrane; Single-pass membrane protein; Secreted

Expression：
Tissue_specificity:Ubiquitous (PubMed:7624800, PubMed:9780177) . Low expression is detected in peripheral blood B cells, T cells, monocytes and in bronchial epithelial cells (at protein level) (PubMed:27043408) . Expressed in plasmablasts or plasma B cells in the lamina propria of ileum, appendix and colon (at protein level) (PubMed:19760593) . Highly expressed on a subset of CD45-positive CD3-positive thymocytes (at protein level) (PubMed:22692454)

Induction: (Microbial infection) Down-regulated upon infection with HHV-1/HSV-1 and HCMV herpesviruses. HSV-1 targets ligand-free MR1 to proteasomal degradation; this process requires de novo viral protein expression with US3 acting as immunoevasin partly responsible for inhibition of MR1 expression and antigen presentation in response to bacterial infection. Whereas HCMV has evolved ways to shut down both ligand-free and ligand-bound MR1 expression

Isoforms & Post-Translational Modification：Q95460 has 5 isomers: Q95460-1: 39366 Da (predicted); Q95460-2: 34278 Da (predicted); Q95460-3: 28973 Da (predicted); Q95460-4: 25933 Da (predicted); Q95460-5: 25190 Da (predicted).
N-glycosylated

Subunit：Heterotrimer that consists of MR1, B2M and a metabolite antigen (PubMed:23051753, PubMed:23846752, PubMed:24695216, PubMed:27043408). Major classes of metabolite ligands presented by MR1 include riboflavin-related antigens, pyrimidines and ribityl lumazines, nucleobase adducts and folate derivatives. Forms reversible covalent Schiff base complexes with microbial pyrimidine-based metabolite, which serves as a molecular switch triggering complete folding, stable association with B2M and translocation of the ternary complex from endoplasmic reticulum to the plasma membrane. Alternatively, forms non-Schiff base complexes with ribityl lumazines (PubMed:23051753, PubMed:23846752, PubMed:24101382, PubMed:24695216, PubMed:26795251, PubMed:27043408, PubMed:32958637, PubMed:39589872, PubMed:39701104). On antigen-presenting cells, the ternary complex interacts with TCR on MR1-restricted T cells, predominantly represented by CD8-positive and CD4- and CD8-double negative MAIT cell subsets (PubMed:24101382, PubMed:23846752, PubMed:24695216, PubMed:26795251). Interacts with TAPBP and TAPBPL chaperones in the endoplasmic reticulum. TAPBP associated or not with MHC class I peptide loading complex binds ligand-free MR1 or MR1-B2M complex, providing for stable MR1 pools ready for metabolite antigen processing. TAPBPL interacts with MR1 in a ligand-independent way; this interaction may stabilize MR1 pool and facilitate ligand loading and dissociation (PubMed:12794138, PubMed:32958637, PubMed:35725941). MR1-B2M heterodimer adopts a topology similar to classical MHC class I molecules, with alpha-1 and alpha-2 domains of MR1 forming the antigen-binding cleft composed of two alpha-helices resting on a floor of 7-stranded anti-parallel beta-pleated sheet (PubMed:23846752, PubMed:24695216, PubMed:26795251). The ribityl moiety of pyrimidine-based antigens is recognized by Tyr-95 residue in the CDR3 alpha loop of the invariant TRAV1-2 TCR (PubMed:23846752, PubMed:24695216, PubMed:26795251)

Synonyms

HLALS

Documentation

User Guide for Antibodies (1077 KB)